AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01086553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: 3mg budesonide TID
Study NCT02036905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical and thoracic mobilization
Description: Described in arm description
Study NCT02036905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical and thoracic manipulation
Description: described in arm description
Study NCT02477020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 20 mg
Description: TAK-063 tablet.
Study NCT02477020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-063 matching-placebo tablet.
Study NCT01766375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A,mycophenolate mofetil,Methotrexate
Description: GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
Study NCT01766375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A,mycophenolate mofetil,Methotrexate
Description: GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
Study NCT00075868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Study NCT00075868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03431194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midodrine
Description: oral midodrine tablets 5 mg
Study NCT03431194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02442921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: up to 2mg of Colchicine daily
Study NCT02442921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo
Study NCT01379326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
Study NCT04660123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
Description: Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.~Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).~Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.~Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.~Antibiotic Program:~Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d.
Study NCT01040429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients \< 35 kg; 50 microgram (2 capsula) x 2/day for patients > 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients \< 35 kg; 25 microgram (2 capsula) x 2/day for patients > 35 kg.
Study NCT01040429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose capsula
Description: Day 1-56 (week 1-8): 1 capsula x 2/day for patients \< 35 kg; 2 capsula x 2/day for patients > 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients \< 35 kg; 1 capsula x 2/day for patients > 35 kg
Study NCT03689127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated breathing circuit on
Description: Heated breathing circuit will be turned on.
Study NCT03689127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated breathing circuit off
Description: Heated breathing circuit will be turned off.
Study NCT01668316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: 1. Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~2. Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~3. Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~4. Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work.
Study NCT00679991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRT-201
Description: Applied topically to AVF during surgery
Study NCT00679991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRT-201
Description: Dose escalation study. Drug/placebo administered at the time of fistula creation
Study NCT00679991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRT-201
Description: Dose escalation study. Drug/placebo administered at the time of fistula creation
Study NCT04226716 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment of postural control, body perception and psychosocial factors
Description: Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception and psychosocial factors (incl. perceived harmfulness of daily activities, pain-related fear of movement, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress, optimism/pessimism, pain coping and coping with stressful life events)
Study NCT02845271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular
Study NCT02845271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ389988
Description: Pharmaceutical form:suspension for injection~Route of administration: intraarticular
Study NCT02845271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen or paracetamol
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02845271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen or paracetamol
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02845271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed combination of paracetamol + codeine
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT02845271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fixed combination of paracetamol + codeine
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT02845271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed combination of paracetamol + tramadol hydrochloride
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02845271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fixed combination of paracetamol + tramadol hydrochloride
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01177072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: 12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
Study NCT01177072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Components-Based Intervention
Description: This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
Study NCT03821571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI
Description: Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
Study NCT03821571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
Study NCT05054296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive general education exercise packet
Study NCT05054296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in supervised and self-directed exercise sessions
Study NCT05054296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit
Description: Wear FitBit for activity tracking
Study NCT05054296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Wear FitBit for activity tracking
Study NCT05054296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05054296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05054296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05054296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03670589 — intervention group
Intervention type: RADIATION
Intervention: Radiosurgery gammaknife
Description: This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor
Study NCT03670589 — intervention group
Intervention type: PROCEDURE
Intervention: Microsurgery resection
Description: Classical surgical approach with oto-neurosurgery procedures
Study NCT04485533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisuXL® Gel
Description: VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day.
Study NCT03911817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge
Study NCT04485533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisuXL® Gel
Description: VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day.
Study NCT04485533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HYLO®
Description: HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day
Study NCT04485533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYLO®
Description: HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day
Study NCT01651741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed and Duolac7S
Description: Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S:~1. The probiotics, Duolac7S, consist of 7 bacteria.~2. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~3. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (30 min after morning and evening meal)~4. Duration: 4 weeks of treatment period
Study NCT01651741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Seaweed and Duolac7S-P
Description: Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).
Study NCT03337776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WhatsApp message
Description: WhatsApp message will be sent to invite subjects to participate in CRC screening
Study NCT03337776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone call
Description: Telephone call will be made to invite subjects to participate in CRC screening
Study NCT03259646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Universal Education
Description: Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
Study NCT01174030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 Gel
Description: CD07805/47 Gel 0.5% QD
Study NCT01174030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle Gel QD
Study NCT01174030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 Gel
Description: CD07805/47 Gel 0.18% QD
Study NCT01174030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 Gel
Description: CD07805/47 Gel 0.18% BID
Study NCT03296059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment with RBC transfusion
Description: Besides conventional treatment, neonates is given RBC transfusion.
Study NCT03296059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: neonates is treated with conventional treatment.
Study NCT02446496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil tablets manufactured by GSK
Description: Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
Study NCT01174030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle Gel BID
Study NCT02446496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil tablets manufactured by NP
Description: Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
Study NCT00796861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
Study NCT01064921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
Study NCT01064921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01064921 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
Study NCT01064921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
Study NCT02496884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 7.5 mg tablet for oral use
Study NCT02496884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet for oral use to match DS-5565 7.5 mg tablet
Study NCT02496884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet for oral use to match DS-5565 7.5 mg tablet
Study NCT01312402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical brinzolamide 1% in 5mL ophthalmic medication
Description: 1 drop three times a day in both eyes on days 2,3 and 4
Study NCT01312402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 5 mL dispenser
Description: Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
Study NCT03606798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 Home visits made by a psychologist
Description: Patient and caregiver interviews with a psychologist at home
Study NCT03745703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOCHA
Description: (see above)
Study NCT00650533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Tablets 1 mg
Description: 1mg, single dose fed
Study NCT00650533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl® Tablets 1 mg
Description: 1mg, single dose fed
Study NCT03006666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Training
Description: CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention.
Study NCT03006666 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Data Only
Description: The teams randomly allocated will not have access to Community Health Workers.
Study NCT00040404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-1347 10mg
Description: CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
Study NCT00040404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP1347 25mg
Description: CEP1347 25mg, a K252a derivative, retains neuroprotective properties
Study NCT00040404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-1347 50mg
Description: CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
Study NCT00040404 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo capsules matching the CEP-1347 capsules
Study NCT03574025 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: To telephone the patient/family to look into how the patient is doing, moderate/severe brain damage.
Study NCT02896231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1001
Description: PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.